文献速递乳腺癌放疗

1型神经纤维瘤病乳腺癌患者辅助放疗的安全性与长期结局

Adjuvant Radiation Therapy in Breast Cancer Patients With Neurofibromatosis Type 1: Safety and Long-Term Outcomes.
PubMed 文献 · Adv Radiat Oncol · 2025-10-24

该单中心回顾性研究纳入1995至2023年27例接受手术及辅助放疗的非转移性乳腺癌NF1患者(30个肿瘤),中位随访79个月。10年总生存与癌症特异生存均为68.3%,无≥3级急性或晚期毒性,未观察到放疗诱发恶性肿瘤。

要点

  • NF1乳腺癌患者辅助放疗10年总生存与癌症特异生存均为68.3%。
  • 急性放射性皮炎发生率83.3%,均为1-2级,无≥3级毒性。
  • 淋巴结受累与脉管侵犯与较差生存显著相关。

核心结论

  • 辅助放疗在NF1乳腺癌患者中安全有效,但低级别急性皮肤毒性发生率较高。
  • 未观察到严重长期毒性或放疗诱发恶性肿瘤。

研究设计与样本

  • 回顾性单中心研究,纳入1995至2023年27例接受手术和辅助放疗的非转移性乳腺癌NF1患者(30个肿瘤)。
  • 分析临床、病理、治疗及毒性数据,生存采用Kaplan-Meier法评估,毒性按NCI CTCAE分级。

主要发现

  • 中位随访79个月,10年总生存率和癌症特异生存率均为68.3%,无转移生存率为68.4%。
  • 局部控制和局部区域控制均超过92%。
  • 急性放射性皮炎发生于83.3%的患者,均为1-2级;未观察到≥3级急性或晚期毒性。
  • 晚期毒性罕见且轻微,未报告放疗诱发恶性肿瘤或心肺事件。
  • 淋巴结受累和脉管侵犯与较差生存显著相关。

关键数值与推荐

  • 10年总生存率68.3%,癌症特异生存率68.3%,无转移生存率68.4%。
  • 局部和局部区域控制均超过92%。
  • 急性放射性皮炎发生率83.3%(1-2级),≥3级急性或晚期毒性为0。

临床怎么用

  • NF1乳腺癌患者可考虑辅助放疗,但需重视低级别急性皮肤毒性的管理。
  • 应优先采用现代剂量 sparing 技术以减少毒性。
  • 需进一步前瞻性研究优化该高危人群的治疗策略。

局限性

  • 回顾性单中心设计,样本量小(27例患者、30个肿瘤)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Neurofibromatosis type 1 (NF1) is a rare autosomal dominant disorder associated with an increased risk of cancer, including a 5-fold higher incidence of breast cancer. Preclinical data suggest heightened radiosensitivity in NF1, raising concerns about toxicity and secondary malignancies after radiation therapy. Clinical data, however, are lacking. This study aimed to evaluate long-term outcomes and treatment-related toxicities in NF1 patients receiving adjuvant radiation therapy for breast cancer. METHODS AND MATERIALS: This retrospective single-center study included 27 NF1 patients with nonmetastatic breast cancer treated with surgery and adjuvant radiation therapy between 1995 and 2023. Clinical, pathologic, treatment, and toxicity data were analyzed. Survival was assessed using Kaplan-Meier estimates, and toxicities were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events. RESULTS: Among 27 patients (30 tumors), the median follow-up was 79 months. The 10-year overall and cancer-specific survival rates were 68.3% each, and the metastasis-free survival rate was 68.4%. Local and locoregional control exceeded 92%. Acute radiodermatitis occurred in 83.3% of patients (grade 1-2); no grade ≥ 3 acute or late toxicity was observed. Late toxicities were rare and mild. No radiation-induced malignancy or cardiopulmonary events were reported. Nodal involvement and lymphovascular invasion were significantly associated with poorer survival. CONCLUSIONS: Adjuvant radiation therapy is safe and effective in NF1 patients with breast cancer, despite a notably high incidence of low-grade acute skin toxicity. No serious long-term toxicity or radiation-induced malignancy was observed. Modern dose-sparing techniques should be prioritized, and further prospective studies are needed to refine treatment approaches in this high-risk group.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Benmatallah C, Kirova Y, Loap P, et al. Adjuvant Radiation Therapy in Breast Cancer Patients With Neurofibromatosis Type 1: Safety and Long-Term Outcomes. Adv Radiat Oncol. 2025. PMID: 41487701. doi:10.1016/j.adro.2025.101931

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。